Sussex scientists to investigate impact of genetic mutations for aggressive blood cancer
University of Sussex researchers have been awarded funding from an international charity to research how certain genetic mutations worsen survival rates in the disease, acute myeloid leukaemia (AML).
Funding from Worldwide Cancer Research will support research into previously unexplored avenues of Wilms tumor-1 (WT1) gene mutations, frequently found in AML. This latest research has the potential to develop new targeted therapies for patients, which are less toxic and more precise than current chemotherapies.